These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 33787601)

  • 1. Analysis of clinical characteristics and prognosis of patients with peripheral T-cell lymphoma.
    Liang X; Guo L; Hu X; Li S; Wen S
    Medicine (Baltimore); 2021 Apr; 100(13):e25194. PubMed ID: 33787601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
    [No Abstract]   [Full Text] [Related]  

  • 3. A retrospective study of the CHOP, CHOPE, and CHOPE/G regimens as the first-line treatment of peripheral T-cell lymphomas.
    Liu X; Yang M; Wu M; Zheng W; Xie Y; Zhu J; Song Y; Liu W
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):443-449. PubMed ID: 30511217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.
    Shibata Y; Hara T; Kasahara S; Yamada T; Sawada M; Mabuchi R; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Kito Y; Goto N; Miyazaki T; Takami T; Takeuchi T; Shimizu M; Tsurumi H
    Hematol Oncol; 2017 Jun; 35(2):163-171. PubMed ID: 26449182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and outcomes of patients with diffuse large B cell lymphoma treated with R-CHOP-like or CHOP-like regimens: an 8-year experience from a single center.
    Huang H; Fan L; Fu D; Lin Q; Shen J
    Ann Palliat Med; 2020 Jul; 9(4):1442-1452. PubMed ID: 32648457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas.
    Niitsu N; Okamoto M; Nakamine H; Aoki S; Motomura S; Hirano M
    Hematol Oncol; 2008 Sep; 26(3):152-8. PubMed ID: 18395866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinicopathologic characteristics and prognostic analysis of testicular diffuse large B-cell lymphoma].
    Wang Y; Shi ZY; Shi Q; Wang S; Zhang MC; Shen R; He Y; Qiu HL; Yi HM; Dong L; Wang L; Cheng S; Xu PP; Zhao WL
    Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):321-327. PubMed ID: 37357002
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
    Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.
    Abramson JS; Feldman T; Kroll-Desrosiers AR; Muffly LS; Winer E; Flowers CR; Lansigan F; Nabhan C; Nastoupil LJ; Nath R; Goy A; Castillo JJ; Jagadeesh D; Woda B; Rosen ST; Smith SM; Evens AM
    Ann Oncol; 2014 Nov; 25(11):2211-2217. PubMed ID: 25193992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.
    Ellin F; Landström J; Jerkeman M; Relander T
    Blood; 2014 Sep; 124(10):1570-7. PubMed ID: 25006130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical characteristics and prognostic features of 63 HIV-associated diffuse large B-cell lymphoma: a single-center real-world study in China].
    Wang CY; Liu J; Liang XP; Guo BL; Hu RZ; Liu Y
    Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):203-208. PubMed ID: 35405777
    [No Abstract]   [Full Text] [Related]  

  • 12. Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).
    Bachy E; Camus V; Thieblemont C; Sibon D; Casasnovas RO; Ysebaert L; Damaj G; Guidez S; Pica GM; Kim WS; Lim ST; André M; García-Sancho AM; Penarrubia MJ; Staber PB; Trotman J; Hüttmann A; Stefoni V; Re A; Gaulard P; Delfau-Larue MH; de Leval L; Meignan M; Li J; Morschhauser F; Delarue R
    J Clin Oncol; 2022 Jan; 40(3):242-251. PubMed ID: 34843406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores.
    Huh SJ; Oh SY; Lee S; Lee JH; Kim SH; Lee GW; Kim SJ; Kim WS; Lee HS; Jo JC; Kim MJ; Kwon JH; Kim HJ
    Int J Hematol; 2019 Oct; 110(4):438-446. PubMed ID: 31250282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas.
    Jia B; Hu S; Yang J; Zhou S; Liu P; Qin Y; Gui L; Yang S; Lin H; Zhang C; Xing P; Wang L; Dong M; Zhou L; Sun Y; He X; Shi Y
    Hematology; 2016 Oct; 21(9):536-41. PubMed ID: 27077778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.
    Camus V; Thieblemont C; Gaulard P; Cheminant M; Casasnovas RO; Ysebaert L; Damaj GL; Guidez S; Pica GM; Kim WS; Lim ST; Andre M; Gutiérrez N; Penarrubia MJ; Staber PB; Trotman J; Hüttmann A; Stefoni V; Tucci A; Fogarty P; Farhat H; Abraham J; Abarah W; Belmecheri F; Ribrag V; Delfau-Larue MH; Cottereau AS; Itti E; Li J; Delarue R; de Leval L; Morschhauser F; Bachy E
    J Clin Oncol; 2024 May; 42(14):1612-1618. PubMed ID: 38364196
    [No Abstract]   [Full Text] [Related]  

  • 16. [Efficacy of surgery and rituximab in primary gastric diffuse large B-cell lymphoma].
    Huang HW; Jiang YB; Fu TW; Xu T; Chen XC; Jin ZM; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):602-6. PubMed ID: 27535862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 2 study of pegylated liposomal doxorubicin plus cyclophosphamide, vincristine/vindesine, and prednisone in newly diagnosed PTCL: 8-year results.
    Xia ZG; Lv FF; Zhang QL; Liu YZ; Zhang SJ; Liu C; Li XQ; Wen Y; Wu ZY; Hong XN; Guo Y; Cao JN
    Oncologist; 2024 Sep; 29(9):819-e1223. PubMed ID: 38821519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical characteristics and prognostic factors of 40 cases of primary systemic anaplastic large cell lymphoma].
    Chen YK; Yu WJ; Liu H; Wei JY; Qian WB; Jin J
    Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):222-227. PubMed ID: 32311892
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical significance of survivin expression in peripheral T-cell lymphoma].
    Xiang XJ; He YJ; Li YH; Huang H; Xu F
    Ai Zheng; 2006 Jun; 25(6):758-61. PubMed ID: 16764776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Characteristics and Outcomes of AIDS-Related Burkitt Lymphoma in China: A Retrospective Single-Center Study.
    Liu R; Zhao H; Xiao G; Tao Y; Tang X; Feng L; Liao B; Liu B; Guan J; Li L; Chen Z; He H; You H
    Technol Cancer Res Treat; 2024; 23():15330338231214236. PubMed ID: 38179657
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.